Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand

In a regulatory filing, Glenmark Pharma said it launched "SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP (maximum retail price) compared to the innovator brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5 mg) per month".

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ddSkYh
via IFTTT